Arvinas, a biotech spin-out of Yale University, has raised $19.25m to fund development of a new class of drugs based on protein degradation. Of the overall fund, $15m came in the form of a series A round co-led by venture firms Canaan Partners and 5AM Ventures with participation from Connecticut Innovations and Elm Street Ventures.…
Yale’s Arvinas brings in $19.25m
Sep 27, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024